Can I read Cost-Effectiveness of TMC-I in HNSCC on EtoBox?

Cost-Effectiveness of TMC-I in HNSCC by jerinjamespathaparambil is a document available to read on EtoBox.

What is Cost-Effectiveness of TMC-I in HNSCC about?

This research analyzes the cost-effectiveness of combining low-dose nivolumab with triple metronomic chemotherapy (TMC-I) for treating advanced head and neck squamous cell carcinoma in China. The study found that TMC-I provides an additional 0.41 quality-adjusted life years (QALYs) at an incremental cost of ¥47,346.98, resulting in an incremental cost-effectiveness ratio (ICER) of ¥116,374.22/QALY, indicating it is cost-effective at a willingness-to-pay threshold of ¥134,037/QALY but not at ¥44,679/QALY com

Author

jerinjamespathaparambil

Language

EN